The clinical laboratory has become central in the delivery of precision medicine, where the advent of molecular biology has revolutionised the diagnosis and treatment of diseases. Modern DNA and RNA testing offers many advantages over traditional methods for the detection of diseases, where the focus is improving the patient care pathway.

Embracing molecular diagnostics (MDx) has facilitated more streamlined workflows, delivered more accurate diagnoses, accelerated the patient result turnaround time and is enabling the delivery of targeted therapies. These advances have placed an increasing emphasis on diagnostic laboratories and their key role in equipping clinicians to make better and quicker decisions about the right treatment for each patient.

At the forefront of diagnostics, Randox Laboratories have utilised their pioneering multiplex Biochip Array Technology (BAT) within their new range of molecular diagnostic assays, which have been developed specifically to meet the needs of clinical laboratories performing molecular testing.

Familial Hypercholesterolemia (FH) Arrays I & II are rapid, accurate diagnostic tests which enable simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes, commonly implicated in cases of suspected familial hypercholesterolemia.

For research use, the Randox Cardiac Risk Prediction Array simultaneously genotypes 19 SNPs for reliable coronary heart disease risk assessment within one day.

With increasing demand being placed on clinical laboratories, Randox Molecular Diagnostics offer unparalleled cost, time and labour saving testing across a range of therapy areas to meet laboratory needs, with many more applications currently in development.